PRINCETON, NJ / ACCESSWIRE / February 28, 2020 / Sonnet BioTherapeutics, Inc., a company developing innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms, announced today that Jay Cross, Chief Financial Officer, will present a corporate overview at the 40th Annual Cowen Health Care Conference in Boston, MA held March 2-4, 2020.
Sonnet BioTherapeutics Presentation Details:
40th Annual Cowen Health Care Conference
Date: Wednesday, March 4, 2020
Presentation Time: 8:30am ET
About Sonnet BioTherapeutics, Inc.
Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single- or bi-specific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.
Sonnet Biotherapeutics Investor Contact
Alan Lada
Solebury Trout
617-221-8006
alada@soleburytrout.com
SOURCE: Sonnet BioTherapeutics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/578349/Sonnet-BioTherapeutics-to-Present-at-the-40th-Annual-Cowen-Health-Care-Conference
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of…
TUCSON, Ariz., Dec. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – WEED Inc. (OTCQB: BUDZ), (“WEED,”…
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”),…
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP…
Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the…